Articles with public access mandates - Tamer M FouadLearn more
Not available anywhere: 1
Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers
M Kai, T Kogawa, DD Liu, TM Fouad, K Kai, N Niikura, L Hsu, JS Willey, ...
Clinical breast cancer 15 (1), 37-42, 2015
Mandates: US National Institutes of Health
Available somewhere: 23
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor-and HER2-defined subtypes
H Masuda, TM Brewer, DD Liu, T Iwamoto, Y Shen, L Hsu, JS Willey, ...
Annals of oncology 25 (2), 384-391, 2014
Mandates: US National Institutes of Health
Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system
TM Fouad, AMG Barrera, JM Reuben, A Lucci, WA Woodward, ...
The Lancet Oncology 18 (4), e228-e232, 2017
Mandates: US National Institutes of Health
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis
TM Fouad, T Kogawa, DD Liu, Y Shen, H Masuda, R El-Zein, ...
Breast cancer research and treatment 152, 407-416, 2015
Mandates: US National Institutes of Health
Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer
M Mego, H Gao, EN Cohen, S Anfossi, A Giordano, T Sanda, TM Fouad, ...
Journal of Cancer 7 (9), 1095, 2016
Mandates: US National Institutes of Health
Risk factors for inflammatory breast cancer and other invasive breast cancers
C Schairer, Y Li, P Frawley, BI Graubard, RD Wellman, DSM Buist, ...
Journal of the National Cancer Institute 105 (18), 1373-1384, 2013
Mandates: US National Institutes of Health
Acute myeloid leukemia developing in patients with autoimmune diseases
SM Ramadan, TM Fouad, V Summa, SKH Hasan, F Lo-Coco
haematologica 97 (6), 805, 2012
Mandates: US National Institutes of Health
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer
M Mego, H Gao, EN Cohen, S Anfossi, A Giordano, S Tin, TM Fouad, ...
Oncotarget 8 (22), 35656, 2017
Mandates: US National Institutes of Health
Epidemiological risk factors associated with inflammatory breast cancer subtypes
RL Atkinson, R El-Zein, V Valero, A Lucci, TB Bevers, T Fouad, W Liao, ...
Cancer Causes & Control 27, 359-366, 2016
Mandates: US National Institutes of Health
Circulating tumor cells in newly diagnosed inflammatory breast cancer
M Mego, A Giordano, U De Giorgi, H Masuda, L Hsu, M Giuliano, ...
Breast Cancer Research 17, 1-12, 2015
Mandates: US National Institutes of Health
MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer
L Huo, Y Wang, Y Gong, S Krishnamurthy, J Wang, L Diao, CG Liu, X Liu, ...
Modern Pathology 29 (4), 330-346, 2016
Mandates: US National Institutes of Health
Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer …
TM Fouad, NT Ueno, RK Yu, JE Ensor, RH Alvarez, S Krishnamurthy, ...
PloS one 13 (9), e0204372, 2018
Mandates: US National Institutes of Health
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
A Canonici, AL Browne, MFK Ibrahim, KP Fanning, S Roche, NT Conlon, ...
Therapeutic advances in medical oncology 12, 1758835919897546, 2020
Mandates: Health Research Board, Ireland, Irish Research Council
Association of body mass index changes during neoadjuvant chemotherapy with pathologic complete response and clinical outcomes in patients with locally advanced breast cancer
T Kogawa, TM Fouad, C Wei, H Masuda, K Kai, T Fujii, R El-Zein, ...
Journal of Cancer 6 (4), 310, 2015
Mandates: US National Institutes of Health
Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer
EN Cohen, TM Fouad, BN Lee, BK Arun, D Liu, S Tin, ...
Breast cancer research and treatment 176, 545-556, 2019
Mandates: US National Institutes of Health
High HER2/centromeric probe for chromosome 17 fluorescence in situ hybridization ratio predicts pathologic complete response and survival outcome in patients receiving …
T Kogawa, TM Fouad, DD Liu, J Wu, Y Shen, H Masuda, T Fujii, ...
The oncologist 21 (1), 21-27, 2016
Mandates: US National Institutes of Health
Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer
T Kogawa, A Doi, M Shimokawa, TM Fouad, T Osuga, F Tamura, ...
Targeted Oncology 10, 125-133, 2015
Mandates: US National Institutes of Health
Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience
D Ren, H Cheng, X Wang, M Vishnoi, BS Teh, R Rostomily, J Chang, ...
Therapeutic Advances in Medical Oncology 12, 1758835920936151, 2020
Mandates: US National Institutes of Health
BRCA mutations in women with inflammatory breast cancer
AM Gutierrez Barrera, TM Fouad, J Song, R Webster, N Elsayegh, ...
Cancer 124 (3), 466-474, 2018
Mandates: US National Institutes of Health
Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer
E Katsuta, L Yan, M Opyrchal, P Kalinski, K Takabe
Therapeutic advances in medical oncology 13, 17588359211006680, 2021
Mandates: US Department of Defense, US National Institutes of Health
Publication and funding information is determined automatically by a computer program